i(3)so3-galactosylceramide and Multiple-Sclerosis--Chronic-Progressive

i(3)so3-galactosylceramide has been researched along with Multiple-Sclerosis--Chronic-Progressive* in 1 studies

Other Studies

1 other study(ies) available for i(3)so3-galactosylceramide and Multiple-Sclerosis--Chronic-Progressive

ArticleYear
Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis.
    Multiple sclerosis and related disorders, 2023, Volume: 74

    Multiple sclerosis (MS) is an immune-mediated demyelinating disorder of the central nervous system. The glycosphingolipid sulfatide, a lipid particularly enriched in the myelin sheath, has been shown to be involved the maintenance of this specific membrane structure. Sulfatide in cerebrospinal fluid (CSF) may reflect demyelination, a dominating feature of MS. We investigated the diagnostic utility of CSF sulfatide isoform levels to separate different courses or phenotypes of MS disease.. This was a mono-center, cross-sectional study of relapsing-remitting MS (RRMS) (n = 45) and progressive MS (PMS) (n = 42) patients (consisting of primary PMS (n = 17) and secondary PMS (n = 25)) and healthy controls (n = 19). In total, 20 sulfatide isoforms were measured in CSF by liquid chromatography-mass spectrometry.. CSF total sulfatide concentrations, as well as CSF sulfatide isoform distribution, did not differ across the study groups, and their levels were independent of disease course/phenotype, disease duration, time to conversion to secondary PMS, age, and disability in MS patients.. CSF sulfatide isoforms lack diagnostic and prognostic utility as a biomarker for progressive MS.

    Topics: Biomarkers; Cross-Sectional Studies; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Protein Isoforms; Sulfoglycosphingolipids

2023